Refine by
Brain Cancer Articles & Analysis: Older
80 news found
Ilkka Haapala’s PhD dissertation explored the possibility of differentiating tumour types and specific mutations based on DMS. We want to congratulate Ilkka on his successful defense of the dissertation at Tampere University on 11.10.2024! IonVision was used as the DMS in several of the studies. The dissertation found that DMS can be used to identify the most common brain tumour ...
Anuncia Medical Inc. (“Anuncia” or the “Company”), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid (CSF) management systems, is pleased to announce the successful first implant of the Company’s FDA-cleared ReFlow™ Mini Flusher device in tandem with a “sonolucent” cranial plate (Clearfit® Cover, ...
Pancreatic cancer (PC) is a severe disease that is difficult to diagnose in the early stages due to its complex and hidden nature. ...
CD BioSciences now offers a comprehensive portfolio of Nervous System Tissue Microarrays, including Brain Tissue Microarrays and Head & Neck Tissue Microarrays. This comprehensive offering provides researchers with a powerful tool for studying various neurological disorders, including brain tumors, head and neck cancers, and neurodegenerative ...
This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug discovery, cancer research, and tissue engineering. The Centre of Excellence will house state-of-the-art CELLINK bioprinters, including the flagship BIO X6 and BIONOVA X bioprinters, a range of bioinks and the leading bioprinting ...
ByCELLINK
Synaptive Medical has received $900,000 in support from the Ontario government through the Ontario Together Fund. This funding will support Synaptive Medical’s $2.8 million project to expand manufacturing and research and development activities related to the company’s head-only Magnetic Resonance Imaging (MRI) system. The Synaptive MRI is a 0.5T system that was designed to overcome ...
His career has focused on technology development and the application of genomics to cancer biology and human diseases, with research in autism, ADHD, vertigo, brain cancers, rare disease diagnostics and therapeutics. ...
“TGen has long been a pioneer in the field of oncology precision medicine, and we’re looking forward to building on this partnership to help pave the way for single-molecule proteomics to deliver new insights in cancer research.” “We are excited to work with Nautilus in being able to characterize the proteome in DIPG to further our understanding of this ...
This was a very exciting presentation as Richard announced the selection of Reglagene's Clinical Candidate for brain ...
“Together with leading neuro-oncologists and computational biologists, we are bringing evidence-based insights to the treatment of brain cancer patients.” The xCures platform generates Real-time, Regulatory-grade, Clinical data (RRC). It now includes data on over 1,000 brain cancer patients, permitting real-time ...
ByxCures
The study published as part of the special issue of Cancers “Novel Techniques and Technology for Treatment of Brain Tumors”, reports that Spermidine/spermine N1-acetyltransferase 1 (SAT1) inhibition using an ionizable lipid nanoparticle-based siRNA delivery system appears to provide a safe and effective method to sensitizing GB cells to radiation and ...
“Glioblastoma remains one of the most aggressive and difficult to treat cancers globally and we believe that targeted radiotherapy and particularly ITM-31 can make a significant impact for patients by selectively eliminating tumor remnants post-surgery,” said Steffen Schuster, CEO of ITM. ...
Cerebral Therapeutics is combining advanced micro-dosing technology with proprietary medications to precisely deliver treatments to the other side of the blood-brain barrier to improve the lives of patients with uncontrolled neurological disease. With a promising route of administration, Cerebral Therapeutics offers a new approach to managing neurological diseases by means of ...
Ocean Biomedical is currently developing five promising discoveries that have the potential to achieve life-changing outcomes in lung cancer, brain cancer, pulmonary fibrosis, and the prevention and treatment of malaria. ...
Ocean Biomedical is currently developing five promising discoveries that have the potential to achieve life-changing outcomes in lung cancer, brain cancer, pulmonary fibrosis, and the prevention and treatment of malaria. ...
Chirinjeev Kathuria commented, “Our executive team and our scientists are excited to partner with Aesther Healthcare to advance our cancer, fibrosis, and malaria discoveries into their Phase 1 trials, which have the potential to save tens of thousands of lives, including people suffering from Glioblastoma Multiforme, one of the most devastating forms of ...
Providence, Rhode Island-based Ocean Biomedical is developing treatments for malaria and different cancer types. Ocean has since announced that it has discovered biospecific antibodies to target specific brain and lung cancers. ...
“Glioblastoma Multiforme is the deadliest form of Brain Cancer, yet the standard of care has not changed for newly diagnosed GBM since 2005. ...
Peptide drug conjugate (PDC) is emerging as a novel type of conjugate drug, showing advantageous features over antibody-drug conjugates (ADCs). As a dedicated peptide manufacturer, Creative Peptides provides a one-stop solution for all peptide drug bioconjugation needs to help pharmaceutical clients bring more PDCs to the market. Structurally, PDC mainly contains three elements—cytotoxin, ...
They are being used to target non-small cell lung cancer and glioblastoma multiforme, a devastating form of brain cancer. ...